Adam Simmons, MPH

  • 3Articles
  • 39.2KReads
  • 2020–2023Active
  • 17Collaborators
  • 81Citations

About

Adam Simmons, MPH is affiliated with Alkermes, Inc., Waltham, Massachusetts. Adam Simmons has authored or co-authored 3 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 2020 and 2023. Their work focuses on Schizophrenia/Schizoaffective Disorders and Weight.

Publications

JCP
Olanzapine/Samidorphan Mitigates Weight Gain in Early Illness
Original Research

Olanzapine/Samidorphan Mitigates Weight Gain in Early Illness

March 22, 2023

In patients with early-phase schizophrenia or bipolar disorder, combination olanzapine and samidorphan resulted in less weight gain at week 12 than olanzapine alone. Antipsychotic efficacy was similar between the...
, , , et al
JCP
Original Research

Olanzapine Plus Samidorphan in Schizophrenia With AUD

March 10, 2020

Alcohol use disorder is comorbid in 33% of US patients with schizophrenia. Testing the tolerability of olanzapine and samidorphan until the first event of exacerbation of disease symptoms is...
, , , et al
JCP
Original Research

Olanzapine/Samidorphan for Schizophrenia

March 3, 2020

Read a study evaluating the antipsychotic efficacy and safety of OLZ/SAM compared with placebo in patients with an acute exacerbation of schizophrenia.
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe